The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.
The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments.
In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
The companies will build and screen novel DNA-encoded libraries for use by Pfizer in its drug discovery efforts.
Two more papers from a former Pfizer cancer researcher have been retracted, as Retraction Watch reports.
The partners will work together to adapt a new chemical synthesis technology for DNA-encoded library creation.
The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.
The company has also announced a collaboration with Pfizer to develop a blood-based assay to identify critical-stage cardiometabolic conditions.
Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.
By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.
Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.
In Nature this week: a Danish reference genome, and more.
